Literature DB >> 29339325

Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.

Min Yan1, Ziyang Liu2, Erkang Fei2, Wenbing Chen2, Xinsheng Lai2, Bin Luo2, Peng Chen2, Hongyang Jing2, Jin-Xiu Pan3, Michael H Rivner4, Wen-Cheng Xiong5, Lin Mei6.   

Abstract

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction (NMJ). Most cases of MG are caused by autoantibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4). Recent studies have identified anti-agrin antibodies in MG patients lacking these three antibodies (i.e., triple negative MG). Agrin is a basal lamina protein that has two isoforms. Neural agrin (N-agrin) binds to LRP4 to activate MuSK to induce AChR clusters and is thus critical for NMJ formation. We demonstrate that mice immunized with N-agrin showed MG-associated symptoms including muscle weakness, fragmented and distorted NMJs. These effects were not observed in mice injected with muscle agrin (M-agrin), an isoform that is inactive in inducing AChR clusters. Treatment with anti-N-agrin, but not anti-M-agrin, antibodies reduced agrin-induced AChR clusters in muscle cells. Together, these observations suggest that agrin antibodies may be play a role in MG pathogenesis.
Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  agrin; antibodies; myasthenia gravis; neuromuscular junction

Mesh:

Substances:

Year:  2018        PMID: 29339325      PMCID: PMC5942223          DOI: 10.1016/j.neuroscience.2018.01.015

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

Review 1.  Myasthenia gravis.

Authors:  A Vincent; J Palace; D Hilton-Jones
Journal:  Lancet       Date:  2001-06-30       Impact factor: 79.321

2.  The immunopathological basis of acetylcholine receptor deficiency in myasthenia gravis.

Authors:  A G Engel
Journal:  Prog Brain Res       Date:  1979       Impact factor: 2.453

3.  Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK).

Authors:  Smita Jha; Kaiping Xu; Takahiro Maruta; Minako Oshima; Dennis R Mosier; M Zouhair Atassi; Werner Hoch
Journal:  J Neuroimmunol       Date:  2006-05-11       Impact factor: 3.478

4.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

5.  Clinical heterogeneity of seronegative myasthenia gravis.

Authors:  A Evoli; A P Batocchi; M Lo Monaco; S Servidei; L Padua; L Majolini; P Tonali
Journal:  Neuromuscul Disord       Date:  1996-05       Impact factor: 4.296

Review 6.  Agrin isoforms and their role in synaptogenesis.

Authors:  U J McMahan; S E Horton; M J Werle; L S Honig; S Kröger; M A Ruegg; G Escher
Journal:  Curr Opin Cell Biol       Date:  1992-10       Impact factor: 8.382

7.  Clinical aspects of MuSK antibody positive seronegative MG.

Authors:  D B Sanders; K El-Salem; J M Massey; J McConville; A Vincent
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

8.  Agrin and synaptic laminin are required to maintain adult neuromuscular junctions.

Authors:  Melanie A Samuel; Gregorio Valdez; Juan C Tapia; Jeff W Lichtman; Joshua R Sanes
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

9.  Draft Genome Sequence of Bacteroidales Strain TBC1, a Novel Isolate from a Methanogenic Wastewater Treatment System.

Authors:  Dieter M Tourlousse; Norihisa Matsuura; Liwei Sun; Mayu Toyonaga; Kyohei Kuroda; Akiko Ohashi; Rodrigo Cruz; Takashi Yamaguchi; Yuji Sekiguchi
Journal:  Genome Announc       Date:  2015-10-08

10.  Autoantibodies to agrin in myasthenia gravis patients.

Authors:  Bin Zhang; Chengyong Shen; Beverly Bealmear; Samia Ragheb; Wen-Cheng Xiong; Richard A Lewis; Robert P Lisak; Lin Mei
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

View more
  12 in total

Review 1.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

2.  Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4.

Authors:  Kai Zhao; Chengyong Shen; Lei Li; Haitao Wu; Guanglin Xing; Zhaoqi Dong; Hongyang Jing; Wenbing Chen; Hongsheng Zhang; Zhibing Tan; Jinxiu Pan; Lei Xiong; Hongsheng Wang; Wanpeng Cui; Xiang-Dong Sun; Shihua Li; Xinping Huang; Wen-Cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2018-08-31       Impact factor: 6.167

Review 3.  Novel pathophysiological insights in autoimmune myasthenia gravis.

Authors:  Gianvito Masi; Kevin C O'Connor
Journal:  Curr Opin Neurol       Date:  2022-08-04       Impact factor: 6.283

4.  Impaired signaling for neuromuscular synaptic maintenance is a feature of Motor Neuron Disease.

Authors:  Qiao Ding; Kaamini Kesavan; Robert D Henderson; Pamela A McCombe; Rosalind L Jeffree; William D Phillips; Ernst J Wolvetang; Shyuan T Ngo; Peter G Noakes; Kah Meng Lee; Elyse Wimberger; Thomas Robertson; Melinder Gill; Dominique Power; Jeryn Chang; Atefeh T Fard; Jessica C Mar; Susan Heggie; Michael J Colditz; Massimo A Hilliard; Dominic C H Ng; Frederik J Steyn
Journal:  Acta Neuropathol Commun       Date:  2022-04-25       Impact factor: 7.578

Review 5.  Understanding the burden of refractory myasthenia gravis.

Authors:  Christiane Schneider-Gold; Tim Hagenacker; Nico Melzer; Tobias Ruck
Journal:  Ther Adv Neurol Disord       Date:  2019-03-01       Impact factor: 6.570

Review 6.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

Review 7.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

8.  Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis.

Authors:  Zheng Yu; Meiying Zhang; Hongyang Jing; Peng Chen; Rangjuan Cao; Jinxiu Pan; Bin Luo; Yue Yu; Brandy M Quarles; Wencheng Xiong; Michael H Rivner; Lin Mei
Journal:  Neurology       Date:  2021-07-07       Impact factor: 11.800

Review 9.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

10.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.